Glatiramer acetate: A novel therapeutic approach in Crohn's disease?

Inflammatory Bowel Diseases

Volumn 15, Issue 1, 2009, Pages 156-

  Neesse, Albrecht ^a   Michl, Patrick ^a   Kunsch, Steffen ^a   Gress, Thomas M ^a   Steinkamp, Martin ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; METHOTREXATE; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ABDOMINAL PAIN; ADULT; ANAMNESIS; CASE REPORT; CROHN DISEASE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; FECES INCONTINENCE; HUMAN; INTESTINAL BLEEDING; LETTER; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION;

ADULT; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 61949455575     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20537     Document Type: Letter

References (10)

1. Teitelbaum D, Webb C, Meshorer A, et al. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol. 1973;3:273-279.
2. Arnon R, Teitelbaum D, Sela M. Suppression of experimental allergic encephalomyelitis by COP1-relevance to multiple sclerosis. Isr J Med Sci. 1989;25:686-689.
3. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987;317: 408-414.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268-1276.
5. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci U S A. 1994; 91:4872-4876.
6. Aharoni R, Teitelbaum D, Sela M, et al. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1997; 94:10821-10826.
7. Aharoni R, Kayhan B, Arnon R. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm Bowel Dis. 2005;11:106-115.
8. Aharoni R, Kayhan B, Brenner O, et al. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease. J Pharmacol Exp Ther. 2006;318:68-78.
9. Aharoni R, Sonego H, Brenner O, et al. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett. 2007;112:110-119.
10. Schott E, Paul F, Wuerfel JT, et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol. 2007; 13:3638-3640.